A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: Effect on inflammation, psychopathology, cognition and lipid metabolism

Schizophrenia Research

Volumn 159, Issue 2-3, 2014, Pages 395-403

  Vincenzi, Brenda ^a   Stock, Shannon ^b   Borba, Christina P C ^c   Cleary, Sarah M ^a   Oppenheim, Claire E ^a   Petruzzi, Liana J ^a   Fan, Xiaoduo ^d   Copeland, Paul M ^a   Freudenreich, Oliver ^c   Cather, Corinne ^c   Henderson, David C ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Center for Interdisciplinary Studies   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

C reactive protein; Cognitive functioning; Glucose metabolism; Inflammation; Psychosis; Statins

Indexed keywords

ARIPIPRAZOLE; C REACTIVE PROTEIN; CHLORPROMAZINE; CLOZAPINE; GLUCOSE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOXAPINE; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PLACEBO; PRAVASTATIN; QUETIAPINE; RISPERIDONE; TIOTIXENE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ZIPRASIDONE; HYPOCHOLESTEROLEMIC AGENT;

ADULT; ANTHROPOMETRY; ARTICLE; CHOLESTEROL BLOOD LEVEL; COGNITION; CONTROLLED STUDY; FEMALE; GLUCOSE METABOLISM; HEAD COLD; HEADACHE; HUMAN; INFLAMMATION; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PERFORMANCE; MUSCLE DISEASE; MUSCLE SORENESS; NEUROLOGIC DISEASE; PILOT STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; COGNITION DISORDERS; DRUG EFFECTS; DRUG POTENTIATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

ADULT; ANTICHOLESTEREMIC AGENTS; COGNITION DISORDERS; DRUG SYNERGISM; FEMALE; HUMANS; INFLAMMATION; LIPID METABOLISM; MALE; MIDDLE AGED; PILOT PROJECTS; PRAVASTATIN; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84922419106     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.08.021     Document Type: Article

References (44)

1. Agrawal A. CRP after 2004. Mol. Immunol. 2005, 42(8):927-930.
2. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br. J. Psychiatry Suppl. 1989, (7):49-58.
3. Ansar W., Ghosh S. C-reactive protein and the biology of disease. Immunol. Res. 2013, 56(1):131-142.
4. Asanuma Y., Oeser A., Stanley E., Bailey D.G., Shintani A., Stein C.M. Effects of C-reactive protein and homocysteine on cytokine production: modulation by pravastatin. Arch. Drug Inf. 2008, 1(1):14-22.
5. Black S., Kushner I., Samols D. C-reactive protein. J. Biol. Chem. 2004, 279(47):48487-48490.
6. Brown A.S., Hooton J., Schaefer C.A., Zhang H., Petkova E., Babulas V., Perrin M., Gorman J.M., Susser E.S. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am. J. Psychiatry 2004, 161(5):889-895.
7. Chew L.J., Fusar-Poli P., Schmitz T. Oligodendroglial alterations and the role of microglia in white matter injury: relevance to schizophrenia. Dev. Neurosci. 2013, 35(2-3):102-129.
8. del Sol A.I., Nanayakkara P.W. Pravastatin: an evidence-based statin?. Expert Opin. Drug Metab. Toxicol. 2008, 4(6):821-825.
9. Dickerson F., Stallings C., Origoni A., Boronow J., Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr. Res. 2007, 93(1-3):261-265.
10. Endicott J., Spitzer R.L., Fleiss J.L., Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry 1976, 33(6):766-771.
11. Fan X., Pristach C., Liu E.Y., Freudenreich O., Henderson D.C., Goff D.C. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res. 2007, 149(1-3):267-271.
12. Fan X., Liu E.Y., Freudenreich O., Park J.H., Liu D., Wang J., Yi Z., Goff D., Henderson D.C. Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. Schizophr. Res. 2010, 118(1-3):211-217.
13. Forero-Pena D.A., Gutierrez F.R. Statins as modulators of regulatory T-cell biology. Mediat. Inflamm. 2013, 2013:167086.
14. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18(6):499-502.
15. Gilmore J.H., Fredrik Jarskog L., Vadlamudi S., Lauder J.M. Prenatal infection and risk for schizophrenia: IL-1beta, IL-6, and TNFalpha inhibit cortical neuron dendrite development. Neuropsychopharmacology 2004, 29(7):1221-1229.
16. Güçlü F., Özmen B., Hekimsoy Z., Kirmaz C. Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed. Pharmacother. 2004, 58(10):614-618.
17. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
18. Heinrichs D.W., Hanlon T.E., Carpenter W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984, 10(3):388-398.
19. Kaesemeyer W.H., Caldwell R.B., Huang J., Caldwell R.W. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J. Am. Coll. Cardiol. 1999, 33(1):234-241.
20. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
21. Kern R.S., Nuechterlein K.H., Green M.F., Baade L.E., Fenton W.S., Gold J.M., Keefe R.S., Mesholam-Gately R., Mintz J., Seidman L.J., Stover E., Marder S.R. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am. J. Psychiatry 2008, 165(2):214-220.
22. Levine J., Schooler N.R. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol. Bull. 1986, 22(2):343-381.
23. Libby P., Tabas I., Fredman G., Fisher E.A. Inflammation and its resolution as determinants of acute coronary syndromes. Circ. Res. 2014, 114(12):1867-1879.
24. Martinez-Gras I., Garcia-Sanchez F., Guaza C., Rodriguez-Jimenez R., Andres-Esteban E., Palomo T., Rubio G., Borrell J. Altered immune function in unaffected first-degree biological relatives of schizophrenia patients. Psychiatry Res. 2012, 200(2-3):1022-1025.
25. Maury E., Brichard S.M. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol. Cell. Endocrinol. 2010, 314(1):1-16.
26. McAllister C.G., van Kammen D.P., Rehn T.J., Miller A.L., Gurklis J., Kelley M.E., Yao J., Peters J.L. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am. J. Psychiatry 1995, 152(9):1291-1297.
27. McNamara J.R., Schaefer E.J. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin. Chim. Acta 1987, 166(1):1-8.
28. Meyer U., Feldon J., Yee B.K. A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophr. Bull. 2009, 35(5):959-972.
29. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70(7):663-671.
30. Miller B.J., Culpepper N., Rapaport M.H., Buckley P. Prenatal inflammation and neurodevelopment in schizophrenia: a review of human studies. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 42:92-100.
31. Miller B.J., Culpepper N., Rapaport M.H. C-reactive protein levels in schizophrenia: a review and meta-analysis. Clin. Schizophr. Relat. Psychoses 2014, 7(4):223-230.
32. Muller N., Myint A.M., Schwarz M.J. Immunological treatment options for schizophrenia. Curr. Pharm. Biotechnol. 2012, 13(8):1606-1613.
33. Najjar S., Pearlman D.M. Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophr. Res. 2014, 10.1016/j.schres.2014.04.041.
34. Otvos J.D. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin. Lab. 2002, 48(3-4):171-180.
35. Patterson T.L., Goldman S., McKibbin C.L., Hughs T., Jeste D.V. UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr. Bull. 2001, 27(2):235-245.
36. Pearson T.A., Ballantyne C.M., Veltri E., Shah A., Bird S., Lin J., Rosenberg E., Tershakovec A.M. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am. J. Cardiol. 2009, 103(3):369-374.
37. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999, 100(3):230-235.
38. Ridker P.M., Rifai N., Clearfield M., Downs J.R., Weis S.E., Miles J.S., Gotto A.M. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 2001, 344(26):1959-1965.
39. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., Pfeffer M.A., Braunwald E. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 2005, 352(1):20-28.
40. Ridker P.M., Morrow D.A., Rose L.M., Rifai N., Cannon C.P., Braunwald E. Relative efficacy of atorvastatin 80mg and pravastatin 40mg in achieving the dual goals of low-density lipoprotein cholesterol <70mg/dl and C-reactive protein <2mg/l: an analysis of the PROVE-IT TIMI-22 trial. J. Am. Coll. Cardiol. 2005, 45(10):1644-1648.
41. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., Glynn R.J. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008, 359(21):2195-2207.
42. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin. Chem. 1982, 28(6):1379-1388.
43. Wellen K.E., Hotamisligil G.S. Inflammation, stress, and diabetes. J. Clin. Invest. 2005, 115(5):1111-1119.
44. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., Shen Y.C. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J. Clin. Psychiatry 2004, 65(7):940-947.